CompanyPHVSNasdaqLeiden

Pharvaris N.V.

Pharvaris develops oral bradykinin B2 receptor antagonists for bradykinin-mediated angioedema.

SEC EDGAR ClinicalTrials.gov pharvaris.com

424B4Sep 28Latest SEC filing

Sep 8Latest story

September 2026

Pharvaris reports positive Phase 3 CHAPTER-3 results for deucrictibant XR in HAE prophylaxis

Sep 8Clinical readoutPharvaris N.V.

Pharvaris reports positive CHAPTER-3 Phase 3 data for deucrictibant XR in HAE prophylaxis

Sep 8Regulatory decisionPharvaris N.V.

August 2026

Pharvaris reports Q2 2026 results, expects CHAPTER-3 data in third quarter

Aug 12Regulatory milestonePharvaris N.V.